(Q37868449)

24 August 2017

1 reference

title

Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes (English)

1 reference

24 August 2017

0 references

David K Chang

3

0 references

Marina Pajic

object named as

Marina Pajic

1

0 references

Andrew Biankin

object named as

Andrew V Biankin

5

0 references

author name string

Christopher J Scarlett

2

1 reference

24 August 2017

Robert L Sutherland

4

1 reference

24 August 2017

publication date

23 April 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

130

1 reference

24 August 2017

issue

1

1 reference

24 August 2017

page(s)

93-101

1 reference

Genetic progression and the waiting time to cancer

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

BRCA1 mutations in primary breast and ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

International network of cancer genome projects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

An imageable highly metastatic orthotopic red fluorescent protein model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Xenograft models for the preclinical evaluation of new therapies in acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Hereditary Nonpolyposis Colorectal Cancer: the Syndrome, the Genes, and Historical Perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

How the fanconi anemia pathway guards the genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Efficient tumour formation by single human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Chemosensitivity prediction by transcriptional profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Targeting multidrug resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

A gene-expression signature as a predictor of survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Identification of the breast cancer susceptibility gene BRCA2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Fanconi anemia is associated with a defect in the BRCA2 partner PALB2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-011-0990-0

Wellcome funds cancer database

21 January 2018

1 reference

12 December 2020

An in vivo platform for translational drug development in pancreatic cancer

1 reference

12 December 2020

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors

1 reference

12 December 2020

Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts

1 reference

12 December 2020

Molecular biomarkers to individualise treatment: assessing the evidence

1 reference

12 December 2020

Getting the noise out of gene arrays

1 reference

12 December 2020

Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents

1 reference

12 December 2020

Microarrays: retracing steps

1 reference

12 December 2020

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

1 reference

12 December 2020

Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies.

1 reference

12 December 2020

Initial testing of topotecan by the pediatric preclinical testing program.

1 reference

12 December 2020

Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children

1 reference

12 December 2020

10.1007/S00439-011-0990-0

Identifiers

DOI

1 reference

24 August 2017

1 reference